Moderna Therapeutics Inc. has lowered its sales forecast for 2025 by nearly $1 billion due to potential headwinds, including increased competition in the COVID-19 vaccine market.
The biotech company now expects revenue of between $1.5 billion and $2.5 billion for 2025, mostly in the second half of the year, with the majority coming from its COVID-19 shot and new RSV vaccine. This is a decrease from its previous forecast range of $2.5 billion to $3.5 billion issued in September.
Moderna’s shares closed nearly 17% lower on Monday, alongside other vaccine stocks such as Novavax and BioNTech, which also fell more than 7%.
The company’s CFO, Jamey Mock, cited four factors that could weigh on sales: increased competition in the COVID-19 market, falling vaccination rates, uncertainty around manufacturing contracts with countries, and potential recommendations from the Centers for Disease Control and Prevention for RSV revaccination.
However, Moderna plans to reduce its cash costs by $1 billion and expects to break even on an operating cash basis in 2028. The company is also diversifying its portfolio with 10 new product approvals over the next three years, including a combination shot targeting COVID-19 and the flu.
Source: https://www.cnbc.com/2025/01/13/moderna-lowers-2025-sales-forecast.html